Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9238080 | 0.81 | PNMT (0.50) | BCHEACHELMNAADRB2ADRB1 | |
| SCHEMBL16363482 | 0.81 | BCHE (0.51) | BCHEACHELMNACD274HRH1 | |
| SCHEMBL16960713 | 0.78 | PNMT (0.44) | LMNACD274KDM4EALDH1A1 | |
| SCHEMBL3134510 | 0.75 | PDCD1LG2 (0.43) | ADRB2ADRB1PDCD1LG2CD274KMT2A | |
| SCHEMBL10910313 | 0.75 | BCHE (0.53) | BCHEACHEADRB2ADRB1ADRA2C | |
| SCHEMBL3272017 | 0.74 | BCHE (0.55) | BCHEACHELMNAHRH1ADRA2C | |
| SCHEMBL25453552 | 0.74 | MEN1 (0.43) | LMNAKMT2AKDM4EPOLB | |
| SCHEMBL2471237 | 0.73 | LMNA (0.64) | BCHEACHELMNAADRB2ADRB1 | |
| SCHEMBL21345495 | 0.73 | LMNA (0.46) | BCHEACHELMNAADRB2ADRB1 | |
| SCHEMBL16950743 | 0.72 | GABRA1 (0.50) | LMNACD274ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | disclosed |
| US-9907765-B2 | Treatment of connective tissue diseases of the skin | CIPHER PHARMACEUTICALS INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2017-06-08 | — | — | US | disclosed |
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEVELOPMENT A/S (DK) | 2013-09-12 | — | — | US | disclosed |
| US-8426475-B2 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S (DK) | 2013-04-23 | — | — | US | disclosed |
| EP-1719507-B1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | ASTION DEV AS (DK) | 2010-07-14 | — | — | EP | disclosed |
| WO-2006108424-A9 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEV AS (DK) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006108424-A2 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | BCHE 2294/4885ACHE 1875/4885LMNA 391/4885 |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ADRB2, ADRB1, ADRA2A | BCHE 2294/4885ACHE 1875/4885LMNA 391/4885 |
| US-20170157068-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | BCHE 2294/4885ACHE 1875/4885LMNA 391/4885 |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | BCHE 2294/4885ACHE 1875/4885LMNA 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.